Intuitive Surgical Sought Appeals Court Rehearing
Manufacturers of proprietary medical systems must monitor how courts define antitrust liability in aftermarket sales.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Should companies face antitrust liability for restricting third-party components in their proprietary systems?
Intuitive Surgical filed a petition for a rehearing en banc with the Ninth Circuit, challenging a recent three-judge panel ruling that revived antitrust claims. The decision could change how companies manage third-party product approvals for their specialized equipment.
Why it matters
The case tests whether manufacturers can face antitrust liability for their approval processes regarding third-party components. An adverse ruling could impact how businesses restrict aftermarket access to their proprietary systems.
The petition follows a panel ruling that allowed a single-brand aftermarket antitrust claim to proceed. The court is currently considering the request for a full-court review following the panel's decision.
The players
Intuitive Surgical
A developer and manufacturer of robot-assisted surgical systems that maintains a significant market position in specialized medical equipment.
Surgical Instrument Service Co.
A company providing repair and support services that is pursuing antitrust claims regarding aftermarket access.
Ninth Circuit
The federal appellate court currently evaluating whether to grant a rehearing en banc for the antitrust dispute.
The details
The appellate panel previously established a legal standard allowing plaintiffs to prove market power in a single-brand aftermarket by demonstrating power in a foremarket. Intuitive Surgical contends that this ruling unfairly penalizes the company for the success of its robot-assisted surgical system. The case specifically examines whether the company's internal approval process for third-party products creates potential antitrust exposure.
Timeline
September 28, 2026: Intuitive Surgical filed its petition for a rehearing.
Market Landscape
This dispute marks a high-stakes challenge to the legal standards governing single-brand aftermarket liability. It follows established antitrust precedents that weigh the balance between a firm's rights to control its ecosystem and a consumer's access to third-party parts.
Operators in the medical device space should track the Ninth Circuit's decision, as it may set a new compliance baseline for managing third-party equipment compatibility. Consult with legal counsel regarding how similar approval processes could create potential exposure to antitrust litigation.
The takeaway
The appellate court's final decision on this rehearing will influence whether proprietary ecosystem controls remain protected or invite increased antitrust scrutiny. Businesses should monitor the court's docket for updates on the en banc request to gauge the potential shift in aftermarket legal risk.
Further reading
For more on industry regulatory trends, see the Healthcare section.
Source note: This article includes information reported by Mlex.
Live Poll
Should companies face antitrust liability for restricting third-party components in their proprietary systems?
